Also known as: %p-tau217
A study in Nature Medicine found that a single blood test model using plasma %p-tau217 can estimate when Alzheimer’s symptoms are likely to begin. In 603 patients, the model linked biomarker positivity with symptom onset, with a median error of 3.0 to 3.7 years.
Researchers at Washington University School of Medicine developed a blood test-based method to predict when Alzheimer's symptoms will begin, with accuracy within three to four years, using plasma p-tau217 protein levels.
Blood-based biomarkers including brain-derived tau and amyloid-beta are enabling earlier Alzheimer's disease diagnosis through non-invasive testing, though confirmatory imaging remains necessary before treatment initiation.
